BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting
Histopathology2016Vol. 69(4), pp. 680–686
Citations Over TimeTop 11% of 2016 papers
Hojabr Kakavand, Emily Walker, Trina Lum, James S. Wilmott, Christina Selinger, Elizabeth Smith, Robyn P.M. Saw, Bing Yu, Wendy A. Cooper, Georgina V. Long, Sandra O’Toole, Richard A. Scolyer
Abstract
The use of IHC is a fast, efficient and cost-effective method to identify single specific mutations in melanoma patients. BRAF(V600E) and NRAS(Q61R) antibodies have high sensitivity and specificity; however, the NRAS(Q61L) antibody appears less sensitive. IHC can help to facilitate the timely, appropriate selection and treatment of metastatic melanoma patients with targeted therapies. Detection of melanoma-associated mutations by IHC may also provide evidence for a diagnosis of melanoma in metastatic undifferentiated neoplasms lacking expression of melanoma antigens.
Related Papers
- → PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer(2021)13 cited
- → MUTATIONAL STATUS AND SOME CLINICO-MORPHOLOGICAL FEATURES OF CUTANEOUS MELANOMA(2017)1 cited
- → Abstract 1094: Deciphering driver mechanisms for tumorigenesis in BRAF/NRAS double wild-type melanoma through integration of heterogeneous genome-wide datasets(2015)
- IMUNOHISTOKEMIJSKI IZRAŽAJ HIF-1α U PRIMARNOM I METASTATSKOM MELANOMU(2014)
- → BRAF and NRAS oncogenes and malignant melanoma(2012)